Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients
Authors:
- Maria Grazia CastagnaMCMaria Grazia Castagna
- Gabriele CeveniniGCGabriele Cevenini
- Alexandra TheodoropoulouATAlexandra Theodoropoulou
- Fabio MainoFMFabio Maino
- Silvia MemmoSMSilvia Memmo
- Cipri ClaudiaCCCipri Claudia
- Valentina BelardiniVBValentina Belardini
- Ernesto BrianzoniEBErnesto Brianzoni
- Furio PaciniFPFurio Pacini
- 1 July 2013
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 169 (1) , 23-29
Abstract
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no evidences are provided regarding the optimal radioactive iodine (RAI) activity to be administered for post-surgical thyroid ablation.Methods: This study aimed to evaluate the impact of RAI activities on the outcome of 225 DTC patients classified as intermediate risk, treated with low (1110–1850 MBq) or high RAI activities (≥3700 MBq).Results: Six to 18 months after ablation, remission was observed in 60.0% of patients treated with low and in 60.0% of those treated with high RAI activities, biochemical disease was found in 18.8% of patients treated with low and in 14.3% of patients treated with high RAI activities, metastatic disease was found in 21.2% of patients treated with low and in 25.7% of patients treated with high RAI activities (P=0.56). At the last follow-up (low activities, median 4.2 years; high activities, median 6.9 years), remission was observed in 76.5% of patients treated with low and in 72.1% of patients treated with high RAI activities, persistent disease was observed in 18.8% of patients treated with low and in 23.5% of patients treated with high RAI activities, recurrent disease was 2.4% in patients treated with low and 2.1% in patients treated with high RAI activities, deaths occurred in 2.4% of patients treated with low and in 2.1% of patients treated with high RAI activities (P=0.87).Conclusion: Our study provides the first evidence that in DTC patients at intermediate risk, high RAI activities at ablation have no major advantage over low activities.Keywords
This publication has 17 references indexed in Scilit:
- A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancerNuclear Medicine Communications, 2012
- Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancerNuclear Medicine Communications, 2012
- Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCiThyroid Research, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patientsEuropean Journal of Endocrinology, 2009
- A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006
- Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 PatientsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Prospective randomized clinical trial to evaluate the optimal dose of131I for remnant ablation in patients with differentiated thyroid carcinomaCancer, 1996
- High or low dose radioiodine ablation of thyroid remnants?European Journal of Nuclear Medicine and Molecular Imaging, 1987